Search Results - subject:"Ankylosing-spondylitis"

The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis

Svedbom, Axel; Dalén, Johan; Ivergård, Moa; Borse, … - In: The European journal of health economics : HEPAC ; … 21 (2020) 1, pp. 45-54

Persistent link: https://www.econbiz.de/10012221637

Cost Effectiveness of Therapeutic Interventions in Ankylosing Spondylitis: A Critical and Systematic Review

Gaujoux-Viala, Ccile; Fautrel, Bruno - In: PharmacoEconomics 30 (2012) 12, pp. 1145-1156

treatment of ankylosing spondylitis (AS). Abstract: Methods:Methods: We performed a systematic search of the databases MEDLINE …

Persistent link: https://www.econbiz.de/10011005078

Cost Effectiveness of Etoricoxib versus Celecoxib and Non-Selective NSAIDS in the Treatment of Ankylosing Spondylitis

Jansen, Jeroen P.; Gaugris, Sabine; Choy, Ernest H.; … - In: PharmacoEconomics 28 (2010) 4, pp. 323-344

Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores, were … the non-selective NSAIDs naproxen (1000 mg/day) and diclofenac (150 mg/day) in the initial treatment of ankylosing … spondylitis (AS) from the UK NHS perspective. Methods: A Bayesian cost-effectiveness model was developed to estimate the costs and …

Persistent link: https://www.econbiz.de/10008602827

Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis

Baji, Petra; Péntek, Márta; Szántó, Sándor; … - In: The European Journal of Health Economics 15 (2014) 1, pp. 45-52

This is the first study which includes a biosimilar drug in the meta-analysis of biological treatments in AS. The results have proven the similar efficacy and safety profile of infliximab-biosimilar treatment compared to other biologicals. </AbstractSection> Copyright Springer-Verlag Berlin Heidelberg 2014

Persistent link: https://www.econbiz.de/10010993915

Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis

Gulyas, Katalin; Bodnar, Nora; Nagy, Zsofia; Szamosi, … - In: The European Journal of Health Economics 15 (2014) 1, pp. 93-100

Although the retention rate to a second-line TNFi was somewhat worse than that to the first-line TNFi, the switching of TNFis is a good therapeutic option in AS patients who failed to respond to the first TNFi. </AbstractSection> Copyright Springer-Verlag Berlin Heidelberg 2014

Persistent link: https://www.econbiz.de/10010993958

Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries

Péntek, Márta; Poór, Gyula; Wiland, Piotr; … - In: The European Journal of Health Economics 15 (2014) 1, pp. 35-43

agents in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Moreover, an estimate is provided on the …

Persistent link: https://www.econbiz.de/10010993964

Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis : systematic literature review and meta-analysis

Baji, Petra; Péntek, Márta; Szántó, Sándor; … - In: The European journal of health economics : HEPAC ; … 15 (2014), pp. 45-52

Persistent link: https://www.econbiz.de/10010376408

Biological therapy in inflammatory rheumatic diseases : issues in Central and Eastern European countries

Péntek, Márta; Poór, Gyula; Wiland, Piotr; … - In: The European journal of health economics : HEPAC ; … 15 (2014), pp. 35-43

Persistent link: https://www.econbiz.de/10010376418

Real-life experience with switching TNF-[alpha] inhibitors in ankylosing spondylitis

Gulyas, Katalin; Bodnar, Nora; Nagy, Zsofia; Szamosi, … - In: The European journal of health economics : HEPAC ; … 15 (2014), pp. 93-100

Persistent link: https://www.econbiz.de/10010378387

Iatrogenic Cost Factors Incorporating Mild and Moderate Adverse Events in the Economic Comparison of Aceclofenac and Other NSAIDs

Peris, Francesc; Martinez, Eduard; Badia, Xavier; Brosa, Max - In: PharmacoEconomics 19 (2001) 7, pp. 779-790

osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Design: A decision analytical model was constructed to represent the …

Persistent link: https://www.econbiz.de/10005590292